vs
MEDIFAST INC（MED）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是MEDIFAST INC的1.7倍（$127.1M vs $75.1M），再鼎医药同比增速更快（17.1% vs -36.9%），MEDIFAST INC自由现金流更多（$-6.6M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -34.4%）
迈德福斯特是一家总部位于美国马里兰州巴尔的摩的营养减重企业，该公司研发、分销并销售减重及健康相关产品，销售渠道涵盖官方网站、多层次营销、电话销售以及品牌加盟减重诊所。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
MED vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.7倍
$75.1M
营收增速更快
ZLAB
高出54.0%
-36.9%
自由现金流更多
MED
多$20.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-34.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.1M | $127.1M |
| 净利润 | — | — |
| 毛利率 | 69.4% | 51.0% |
| 营业利润率 | -10.4% | -54.6% |
| 净利率 | — | — |
| 营收同比 | -36.9% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-1.64 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDZLAB
| Q4 25 | $75.1M | $127.1M | ||
| Q3 25 | $89.4M | $115.4M | ||
| Q2 25 | $105.6M | $109.1M | ||
| Q1 25 | $115.7M | $105.7M | ||
| Q4 24 | $119.0M | $108.5M | ||
| Q3 24 | $140.2M | $101.8M | ||
| Q2 24 | $168.6M | $100.1M | ||
| Q1 24 | $174.7M | $87.1M |
净利润MEDZLAB
| Q4 25 | — | — | ||
| Q3 25 | $-2.3M | $-36.0M | ||
| Q2 25 | $2.5M | $-40.7M | ||
| Q1 25 | $-772.0K | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.1M | $-41.7M | ||
| Q2 24 | $-8.2M | $-80.3M | ||
| Q1 24 | $8.3M | $-53.5M |
毛利率MEDZLAB
| Q4 25 | 69.4% | 51.0% | ||
| Q3 25 | 69.5% | 59.5% | ||
| Q2 25 | 72.6% | 60.6% | ||
| Q1 25 | 72.8% | 63.6% | ||
| Q4 24 | 74.1% | 61.5% | ||
| Q3 24 | 75.4% | 64.1% | ||
| Q2 24 | 73.2% | 64.9% | ||
| Q1 24 | 72.8% | 61.4% |
营业利润率MEDZLAB
| Q4 25 | -10.4% | -54.6% | ||
| Q3 25 | -4.6% | -42.3% | ||
| Q2 25 | -1.0% | -50.3% | ||
| Q1 25 | -1.1% | -53.3% | ||
| Q4 24 | 0.6% | -62.6% | ||
| Q3 24 | 1.5% | -66.6% | ||
| Q2 24 | -4.7% | -76.0% | ||
| Q1 24 | 4.5% | -80.7% |
净利率MEDZLAB
| Q4 25 | — | — | ||
| Q3 25 | -2.5% | -31.2% | ||
| Q2 25 | 2.3% | -37.3% | ||
| Q1 25 | -0.7% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.8% | -40.9% | ||
| Q2 24 | -4.8% | -80.2% | ||
| Q1 24 | 4.8% | -61.4% |
每股收益（稀释后）MEDZLAB
| Q4 25 | $-1.64 | $-0.05 | ||
| Q3 25 | $-0.21 | $-0.03 | ||
| Q2 25 | $0.22 | $-0.04 | ||
| Q1 25 | $-0.07 | $-0.04 | ||
| Q4 24 | $0.08 | $-0.09 | ||
| Q3 24 | $0.10 | $-0.04 | ||
| Q2 24 | $-0.75 | $-0.08 | ||
| Q1 24 | $0.76 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.3M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $198.9M | $715.5M |
| 总资产 | $248.0M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MEDZLAB
| Q4 25 | $167.3M | $689.6M | ||
| Q3 25 | $173.5M | $717.2M | ||
| Q2 25 | $162.7M | $732.2M | ||
| Q1 25 | $164.6M | $757.3M | ||
| Q4 24 | $162.3M | $779.7M | ||
| Q3 24 | $170.0M | $616.1M | ||
| Q2 24 | $163.5M | $630.0M | ||
| Q1 24 | $156.4M | $650.8M |
股东权益MEDZLAB
| Q4 25 | $198.9M | $715.5M | ||
| Q3 25 | $214.7M | $759.9M | ||
| Q2 25 | $216.0M | $791.7M | ||
| Q1 25 | $211.0M | $810.8M | ||
| Q4 24 | $210.1M | $840.9M | ||
| Q3 24 | $207.3M | $667.7M | ||
| Q2 24 | $205.3M | $704.2M | ||
| Q1 24 | $211.0M | $762.2M |
总资产MEDZLAB
| Q4 25 | $248.0M | $1.2B | ||
| Q3 25 | $268.2M | $1.2B | ||
| Q2 25 | $269.3M | $1.2B | ||
| Q1 25 | $280.0M | $1.2B | ||
| Q4 24 | $284.2M | $1.2B | ||
| Q3 24 | $291.2M | $985.3M | ||
| Q2 24 | $293.5M | $987.4M | ||
| Q1 24 | $302.8M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-6.6M | $-26.7M |
| 自由现金流率自由现金流/营收 | -8.8% | -21.0% |
| 资本支出强度资本支出/营收 | 1.8% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流MEDZLAB
| Q4 25 | $-5.3M | $-26.0M | ||
| Q3 25 | $12.1M | $-32.0M | ||
| Q2 25 | $-3.4M | $-31.0M | ||
| Q1 25 | $3.4M | $-61.7M | ||
| Q4 24 | $-4.9M | $-55.8M | ||
| Q3 24 | $9.1M | $-26.8M | ||
| Q2 24 | $13.1M | $-42.2M | ||
| Q1 24 | $7.3M | $-90.1M |
自由现金流MEDZLAB
| Q4 25 | $-6.6M | $-26.7M | ||
| Q3 25 | $10.8M | $-35.0M | ||
| Q2 25 | $-4.8M | $-33.9M | ||
| Q1 25 | $1.9M | $-63.2M | ||
| Q4 24 | $-7.2M | $-58.4M | ||
| Q3 24 | $7.7M | $-28.2M | ||
| Q2 24 | $11.1M | $-42.9M | ||
| Q1 24 | $5.4M | $-91.1M |
自由现金流率MEDZLAB
| Q4 25 | -8.8% | -21.0% | ||
| Q3 25 | 12.0% | -30.4% | ||
| Q2 25 | -4.5% | -31.1% | ||
| Q1 25 | 1.6% | -59.9% | ||
| Q4 24 | -6.1% | -53.8% | ||
| Q3 24 | 5.5% | -27.7% | ||
| Q2 24 | 6.6% | -42.9% | ||
| Q1 24 | 3.1% | -104.5% |
资本支出强度MEDZLAB
| Q4 25 | 1.8% | 0.5% | ||
| Q3 25 | 1.5% | 2.6% | ||
| Q2 25 | 1.3% | 2.6% | ||
| Q1 25 | 1.3% | 1.5% | ||
| Q4 24 | 1.9% | 2.4% | ||
| Q3 24 | 1.0% | 1.3% | ||
| Q2 24 | 1.1% | 0.7% | ||
| Q1 24 | 1.1% | 1.1% |
现金转化率MEDZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.36× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.04× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MED
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
